Translocator protein (TSPO) in breast cancer

Current Molecular Medicine

Volumn 12, Issue 4, 2012, Pages 443-457

  Mukherjee, S ^a,b   Das, S K ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b Department of Professional and Medical Education ^*  (United States)

Author keywords

Biomarker; Breast cancer; TSPO

Indexed keywords

4' CHLORODIAZEPAM; ADENINE NUCLEOTIDE TRANSLOCASE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PROTEIN; SOYBEAN PROTEIN; TRANSLOCATOR PROTEIN; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

ADRENAL GLAND; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARDIOVASCULAR SYSTEM; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL TRANSPORT; COLON; CONCENTRATION RESPONSE; DIETARY INTAKE; DRUG TARGETING; HUMAN; KIDNEY; NONHUMAN; OVARY; PLACENTA; PROSTATE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STEROIDOGENESIS; TESTIS; TISSUE DISTRIBUTION;

EID: 84860271388     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011207040443     Document Type: Article

References (143)

1. Costa E, Guidotti A, Mao CC, Suria A. New concepts of the mechanism of action of benzodiazepines. Life Sci 1975; 17: 167-86.
2. Papadopoulos V. Peripheral-type benzodiazepine-diazepam binding inhibitor receptor: biological role in steroidogenic cell function. Endocr Rev 1993; 14: 222-40.
3. 3H] diazepam binding. Proc Natl Acad Sci USA 1977; 74: 3805-9.
4. Regan JW, Yamamura HI, Roeske WR. The benzodiazepine receptor: its development and its modulation by gammaaminobutyric acid. J Pharmacol Exp Ther 1980; 212: 137-43.
5. DeSouza EB, Anholt RRH, Murphy KWM, Synder SH. Peripheral-type benzodiazepine receptor in endocrine organs: autoradiographic localization in rat pituitary, adrenal and testis. Endocrinology 1985; 116: 567-73.
6. Fares FA, Gavish M. Characterization of peripheral benzodiazepine binding sites in human term placenta. Biochem Pharmacol 1986; 35: 227-30.
7. Gehlert DR, Yamamura H, Wamsly JK. Autoradiographic localization of "peripheral" benzodiazepine binding sites in rat brain and kidney. Eur J Pharmacol 1985; 95: 329-30.
8. Ferrarese C, Appollonio I, Frigo, M, et al. Characterization of peripheral benzodiazepine receptors in human blood mononuclear cells. Neuropharmacology 1990; 29: 375-8.
9. McEnery MW, Snowman AM, Trifiletti RR, Snyder SH. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci USA 1992; 89: 3170-4.
10. Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18-kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-9.
11. Shoshan-Barmatz V, Ben-Hall D. VDAC, a multi-functional mitochondria protein as a paharmacological target. Mitochondrion 2011; 12(1): 24-34.
12. Beurdeley-Thomas A, Miccoli L, Oudard S, Dutrillaux B, Poupon MF. The peripheral benzodiazepine receptors: a review. J Neurooncol 2000; 46: 45-56.
13. Mukherjee S, Das SK. Subcellular Distribution of "Peripheral Type" biding sites for [3H] R05-4864 in guinea pig lung. J Biol Chem 1989; 264: 16713-8.
14. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, Arbel N. VDAC, a multi-functional mitochondrial protein regulation cell life and death. Mol Aspects Med 2010; 31: 227-85.
15. Gavish M, Bachman I, Shoukrun R, et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 1999; 51: 629-50.
16. Tallani S, Pugliesi I, Da Settimo F. Structural requirements to obtain highly potent and selective 18-kDa Translocator Protein (TSPO) Ligands Curr Top Med Chem 2011; 11: 860-86.
17. Papadopoulos V. Structure and function of the peripheraltype benzodiazepine receptor in steroidogenic cells. Proc Soc Exp Biol Med 1998; 217: 130-42.
18. Papadopoulos V, Amri H, Li H, Boujrad N, Vidic B, Garnier M. Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits steroidogenesis in the R2C Leydig tumor cell line. J Biol Chem 1997; 272: 32129-35.
19. Lippman ME. The development of biological therapies for breast cancer Science (Washington DC), (1993) 259: 631-632.
20. Rowland JH, Mariotto A, Alfan CM. Cancer survivors-United State 2007. MMWR 2011; 60(9): 269-72.
21. American Cancer Society, Inc. A Presentation from the American Cancer Society. Cancer Statistics 2009.
22. Hodgson SV, Morrison, PJ, Irving, M. Breast cancer genetics: unsolved questions and open perspectives in an expanding clinical practice. Am J Med Genet 2004; 129C: 56-64.
23. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 2002; 111: 115-27.
24. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
25. Miranda PY, Tarraf W, González HM. Breast cancer screening and ethnicity in the United States: implications for health disparities research. Breast Cancer Res Treat 2011: 28(2): 535-42.
26. Ries L, Melbert D, Krapcho M. SEER Cancer Statistic Review, 1975-2004. National Cancer institute Bethesda, MD available via INTERNET http://seercancergov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER website, 2007 cited 2 Feb].
27. Belle FN, Kampman E, McTiernan A, et al. Dietary fiber, carbohydrate, glycemic index, and glycemic load in relation to breast cancer prognosis in the HEAL Cohort. Cancer Epidemiol Biomarkers Prev 2011; 20: 890-9.
28. Spector D, deRoo LA, Sandler DP. Lifestyle behaviors in black and white with a family history of breast cancer. Prev Med 2011; 52(5): 394-7.
29. Silver SR, Whelan EA, Deddens JA, et al. Occupational exposure to polychlorinated biphenyls and risk of breast cancer. Environ Health Perspect 2009; 117(2): 276-82.
30. de Kok IM, van Lenthe FJ, Avendano M, Louwman M, Coebergh JW, Mackenbach JP. Childhood social class and cancer incidence: results of the globe study. Soc Sci Med 2008; 66: 1131-9.
31. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996; 46: 5-27.
32. Tong Y, Rhéaume E, Simard J, Pelletier G. Localization of peripheral benzodiazepine binding sites and diazepambinding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(a)antracene (DMBA)-induced mammary tumors in the rat. Regul Pept 1991; 33: 263-73.
33. Carmel I, Fares FA, Leschiner S, Scherübl H, Weisinger G, Gavish M. Peripheral-type benzodiazepine receptors in the regulation of proliferation of MCF-7 human breast carcinoma cell line. Biochem Pharmacol 1999; 58: 273-8.
34. Landau M, Weizman A, Zoref-Shani E, et al. Antiproliferative and differentiating effects of benzodiazepine receptor ligands on B16 melanoma cells. Biochem Pharmacol 1998; 56: 1029-34.
35. Ikezaki K, Black KL. Stimulation of cell growth and DNA synthesis by peripheral benzodiazepine. Cancer Lett 1990; 49: 115-20.
36. Katz Y, Eitan A, Gavish M. Increase in peripheral benzodiazepine binding sites in colonic adenocarcinoma. Oncology 1990; 47: 139-42.
37. Cornu P, Benavides J, Scatton B, Hauw JJ, Philippon, J. Increase in omega 3 (peripheral-type benzodiazepine) binding site densities in different types of human brain tumours. A quantitative autoradiography study. Acta Neurochir 1992; 119: 146-52.
38. Hardwick M, Fertikh D, Culty M, Li H, Vidic B, Papadopoulos V. Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 1999; 59: 831-42.
39. Katz Y, Ben-Baruch G, Kloog Y, Menczer J, Gavish M. Increased density of peripheral benzodiazepine-binding sites in ovarian carcinomas as compared with benign ovarian tumours and normal ovaries. Clin Sci 1990; 78: 155-8.
40. Han Z, Slack RS, Li W, Papadopoulos V. Expression of peripheral benzodiazepine receptor (PBR) in human tumors: Relationship to breast, colorectal, and prostate tumor progression. J Recep Signal Trans 2003; 23: 225-38.
41. Venturini I, Alho H, Podkletnova I, et al. Increased expression of peripheral benzodiazepine receptors and diazepam binding inhibitor in human tumors sited in the liver. Life Sci 1999; 65: 2223-31.
42. Miettinen H, Kononen J, Haapasalo H, et al. Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res 1995; 55: 2691-5.
43. Mukhopadhyay S, Mukherjee S, Das SK. Increased expression of peripheral benzodiazepine receptor (PBR) in dimethylbenz[a]anthracene-induced mammary tumors in rats. Glycoconjugate J 2006 23: 199-207.
44. Mukherjee S, Mohammad AR, Das SK. Effects of dimethylbenz[a]anthracene-induced malignancy on the subcellular distribution of peripheral benzodiazepine receptors in submandibular glands of rats. Biochem Pharmacol 1990; 40: 1589-94.
45. Brow, RC, Degenhardt B, Kotoula M, Papadopoulos V. Location-dependent role of the human glioma cell peripheraltype benzodiazepine receptor in proliferation and steroid biosynthesis. Cancer Lett 2000; 156: 125-32.
46. Papadopoulos V, Kapsis A, Li H, et al. Drug-induced inhibition of the peripheral-type benzodiazepine receptor expression and cell proliferation in human breast cancer cells. Anticancer Res 2000; 20: 2835-48.
47. Beinlich A, Strohmeier R, Kaufmann M, Kuhl H. Relation of cell proliferation to expression of peripheral benzodiazepine receptors in human breast cancer cell lines. Biochem Pharmacol 2000; 60: 397-402.
48. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-40.
49. 2+ signaling leading to nitric oxide production and endothelial cell adhesion and proliferation. Exp Cell Res 2004; 295: 102-18.
50. Subbaiah PV, Liu M, Witt TR. Impatred cholesterol esterification in the plasma in patients with breast cancer. Lipids 1997; 32: 157-62.
51. Papadopoulos V, Amri H, Boujrad N, et al. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids 1997; 62: 21-8.
52. Hirsch JD, Beyer CF, Malkowitz L, Beer B, Blume AJ. Mitochondrial benzodiazepine receptors mediate inhibition of mitochondrial respiratory control. Mol. Pharmacol 1989; 35: 157-63.
53. Larche, JC, Vayssiere JL, Le Marquer FJ, et al. Effects of peripheral benzodiazepines upon the O2 consumption of neuroblastoma cells. Eur J Pharmacol 1989; 161: 197-202.
54. Carayon P, Portier M, Dussossoy D, et al. Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage. Blood 1996; 87: 3170-8.
55. Papadopoulos V, Dharmarajan AM, Li H, Culty M, Lemay M, Sridaran R. Mitochondrial peripheral-type benzodiazepine receptor expression. Correlation with gonadotropin-releasing hormone (GnRH) agonist-induced apoptosis in the corpus luteum. Biochem Pharmacol 1999; 58: 1389-93.
56. Li H, Papadopoulos V. Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern. Endocrinology 1998; 139: 4991-7.
57. Li H, Yao Z, Degenhardt B, Tepe G, Papadopoulos V. Cholesterol binding at the cholesterol recognition/ interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide. Proc Natl Acad Sci USA 2001; 98: 1267-72.
58. Delavoie F, Li H, Hardwick M, et al. In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry 2003; 42: 4506-19.
59. Costa B, Pini S, Gabelloni P, et al. The spontaneous Ala147Thr amino acid substitution within the translocator protein influences pregnenolone production in lymphomonocytes of healthy individuals. Endocrinology 2009; 150: 5438-45.
60. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999; 59: 80-4.
61. Katz-Brull R, Seger D, Rivenson-Sega D, Degani H. Metabolic markers of breast cancer: Enhanced choline metabolism and reduced choline-ether-phospholipid synthesis, Cancer Res 2002; 62: 1966-70.
62. Mukherjee S, Chatterjee D, Das SK. Cholinephosphotransferase. In: Lipids: Glycerolipid Metabolizing Enzymes (Haldar D and Das SK, eds), Research Signpost 2002; 85-107.
63. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2002; 61: 3599-603.
64. Preul M, Caramanos Z, Collins DL, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nature Med 1996; 2: 323-5.
65. Li XL, Pirzkall A, McKnight T, Nelson SJ. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Im 2002; 16: 229-37.
66. Ghosh A, Akech J, Mukherjee S, Das SK. Differential expression of cholinephosphotransferase in normal and cancerous human mammary epithelial cells. Biochem Biophys Res Commun 2002; 297: 1043-8.
67. Sinha Roy S, Mukhopadhyay S, Mukherjee S, Das SK. Breast cancer is associated with an increase in the activity and expression of cholinephosphotransferase in rats. Life Sci 2008; 83: 661-5.
68. Sutter AP, Maaser K, Barthel B, Scherubl H. Ligands of the peripheral benzodiazepine receptor induces apoptosis and cell cycle arrest in oesophageal cancer cells: involvement of the p38MAPK signaling pathway. Br J Cancer 2003: 89:564-72.
69. Sutter AP, Maaser K, Gerst B, Krahn A, Zeitz M, Scherubl H. Enhancement of peripheral benzodiazepine receptor ligandinduced apoptosis and cell cycle arrest of esophageal cancer cells by simultaneous inhibition of MAPK/ERK kinase. Biochem Pharmacol 2004; 67: 1701-10.
70. Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D, Scherubl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005; 43: 808-16.
71. Akech J, Sinha Roy S, Das SK. Modulation of cholinephosphotransferase activity in breast cancer cell lines by Ro5-4864, a peripheral benzodiazeoine receptor agonist. Biochem Biophys Res Commun 2005; 333: 35-41.
72. Bussolino DF, Guido ME, Gil GA, et al. c-Fos associates with the endoplasmic reticulum and activates phospholipid metabolism. FASEB J 2001; 15: 556-8.
73. Tamiya-Koizumi K. Nuclear lipid metabolism and signaling. J Biochem 2002; 132: 13-22.
74. Sinha Roy S, Das SK. Phospholipid as Biomarkers for breast cancer. In: Aggressive Breast Cancer, Cancer Etiology, Diagnosis and treatments Series (DeFrina RH. Ed.) Nova Science Publishers, Inc. New York. pp.159-171; 2010.
75. Bussolino DF, Guido ME, Gil GA, et al. c-fos associates with the endoplasmic reticulum and activates phospholipid metabolism. FASEB J 2001; 15: 556-8.
76. Xia W, Spector S, Hardy L, et al. Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine. Proc Natl Acad Sci USA 2000; 97: 7494-9.
77. Katz Y, Amiri Z, Weizman A, Gavish M. Identification and distribution of peripheral benzodiazepine receptor binding sites in male rat genital tract. Biochem Pharmacol 1990; 40: 817-20.
78. Black KL, Ikezaki K, Santori E, Becker DP, Vinters HV. Specific high binding affinity binding of peripheral benzodiazepine receptor ligands to brain tumors in rat and man. Cancer 1990; 65: 93-7.
79. Pawlikowski M, Lyson K, Kunert-Radek J, Stepien H. Effects of benzodiazepine on the proliferation of mouse spleen lymphocytes in vitro. J Neural Transm 1988; 73: 161-6.
80. Black KL, Shiraish T, Ikezaki K, Tabuchi K, Becker DP. Peripheral benzodiazepine stimulates secretion of growth hormone and mitochondrial proliferation in pituitary tumor GH3 cells. Neurol Res 1994; 16: 74-80.
81. Matthew E, Laskin JD, Zimmerman EA, Weinstein IB, Hsu KC, Engelhardt DL. Benzodiazepines have high affinity binding sites and induce melanogenesis in B16/C3 melanoma cells. Proc Natl Acad Sci USA 1981; 78: 3935-9.
82. Wang JKT, Morgan JI, Spector S. Benzodiazepines that bind at peripheral sites inhibits cell proliferation. Proc Natl Acad Sci USA 1984; 81: 753-6.
83. Clarke GD, Ryan PJ. Tranquillizers can block mitogenesis in 3T3 cells and induce differentiation in Friend cells. Nature 1980; 287: 160-1.
84. Beinlich A, Strohmeier R, Kaufmann M, Kuhl H. Specific binding of benzodiazepines to human breast cancer cell lines. Life Sci 1999; 56: 2099-108.
85. Beinlich A, Strohmeier R, Kaufmann M, Kuhl H. Relation of cell proliferation to expression of peripheral benzodiazepine receptors in human breast cancer cell lines. Biochem. Pharmacol 2000; 60: 397-402.
86. Garib V, Niggemann B, Zanker KS, Brandt L, Kubens BS. Influence of non-volatile anesthetics on the migration behavior of the human breast cancer cell line MDA-MB-468. Acta Anaesthesiol. Scand 2002; 46: 836-44.
87. Kupczyk-Subotkowska L, Siahaan TJ, Basile AS, et al. Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate. J Med Chem 1997; 40: 1726-30.
88. Hardwick M, Rone J, Han Z, Haddad B, Papadopoulos V. Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice. Int J Cance 2001; 94(3): 322-7.
89. Mukhopadhyay S, and Das SK. Over expression of peripheral benzodiazepine receptors in breast cancer development. In: Aggressive Breast Cancer, Cancer Etiology, Diagnosis and treatments Series (DeFrina RH. Ed.) Nova Science Publishers, Inc. New York. pp. 141-158; 2010.
90. Galiegue S, Casellas P, Kramar A, Tinel N, Simony-Lafontaine J. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Can Res 2004; 10: 2058-64.
91. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willet WC. Primary Prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343: 15-22.
92. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-7.
93. Sánchez-Zamorano LM, Flores-Luna L, Angeles-Lierenas A, Romieu I, Lazcano-Ponce E, Miranda-Hernández H, Mainero-Ratchelous F, Torres-Mejía G. Healthy life style on the risk of breast cancer. Cancer Epidermiol Biomarkers Prev 2001; 20(5): 912-22.
94. Jebb SA, and Moore MS. Contribution of a sedentary lifestyle and inactivity to the etiology of overweight and obesity: Current evidence and research issues. Med Sci Sports Exerc 1999; 31(11Suppl): S534-41.
95. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997; 29: 95-120.
96. Nagasawa H. Nutrition and breast cancer: a survey of experimental and epidemiological evidence. IRCS J Med Sci 1980; 8: 317-25.
97. Moorman PG, Terry PD. Consumption of dairy products and risk of breast cancer: a review of the literature. Am J Clin Nutr 2004; 80: 5-14.
98. De Stefani E, Ronco A, Mendilaharsu M, Guidobono M, Deneo-Pellegrini H. Meat intake, heterocyclic amines, and risk of breast cancer: a cancer-control study in Uruguay. Cancer Epidemiol. Biomark Pre 1997; 6: 573-81.
99. Constantinou AI, Mehta RG, Vaughan A. Inhibition of Nmethyl-N-nitrosourea-induced mammary tumors in rats by the soybean isoflavones. Anticancer Res 1996; 16: 3293-8.
100. Kennedy AR. The evidence for soybean products as cancer preventive agents. J Nutr 1995; 125: 733S-43S.
101. Adlercreutz H, Honjo H, Higashi A, et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991; 54: 1093-100.
102. Setchell KD, Borriello SP, Hulme P, Kirk DN, Axelson M. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr 1984; 40: 569-78.
103. Axelson M, Sjövall J, Gustafsson BE, Setchell KD. Soya-a dietary source of the non-steroidal oestrogen equol in man and animals. J Endocrinol 1984; 102: 49-56.
104. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113-31.
105. Russo J, Russo IH. Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis. Cancer Res 1980; 40: 2677-87.
106. Geske FJ, Nelson AC, Lieberman R, Strange R, Sun T, Gerschenson LE. DNA repair is activated in early stages of p53-induced apoptosis. Cell Death Differ 2000; 7: 393-401.
107. Sivaraman L, Hilsenbeck SG, Zhong L, et al. Early exposure of the rat mammary gland to estrogen and progesterone blocks co-localization of estrogen receptor expression and proliferation. J Endocrinol 2001; 171: 75-83.
108. D'Cruz CM, Moody SE, Master SR, et al. Persistent parityinduced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol 2002; 16: 2034-51.
109. Mukhopadhyay S, Ballard BR, Mukherjee S, Kabir SM, Das SK. Beneficial effects of soy protein in the initiation and progression against dimethylbenz[a]anthracene-induced breast tumors in female rats. Mol Cell Biochem 2006; 290: 169-76.
110. Mukhopadhyay S, Rajaratnam V, Mukherjee S, Das SK. Control of peripheral benzodiazepine receptor-mediated breast cancer in rats by soy protein. Mol Carcinog 2008; 47: 310-9.
111. McLaughlin JM, Olivo-Marston S, Vitolins MZ, et al. Effect of omato-and Soy-Rich diets on the IGF-I hormonal network: A crossover study of postmenopausal women at high risk for breast cancer. Cancer Prev Res 2011; 4: 702-10.
112. Centers for Disease Control and Prevention. Tobacco Use in the United States. http://www.cdc.gov/tobacco/overview/tobus_us.htm.
113. U.S. Department of Health and Human Services. Report on Carcinogens: Tenth Edition. Research Triangle Park, NC: 2002.
114. International Agency for Research on Cancer. Tobacco Smoke and Involuntary Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 83. Lyon, France, 2004.
115. State of California Air Resources Board and Office of Environmental Health Hazard Assessment. June 2005.
116. Boffetta P, Autlier P. Is breast cancer associated with tobacco smoking? BMJ 2011; 342: d1016.
117. Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB. Cigarette smoking and the incidence of breast cancer. Arch Intern Med 2011; 171: 125-33.
118. Nagler R, Ben-Izhak O, Savulescu D, et al. Oral cancer, cigarette smoke and mitochondria 18-kDa translocator protein (TPSO) -in vitro, in vivo, salivary analysis. Biochim. Biophys Acta 2011; 1802: 454-61.
119. Mukherjee S, Das SK. Mainstream and Sidestream Cigarette Smoking Induces Overexpression of TSPO and Cell Proliferation in Human Breast Cancer Cell Lines. Experimental Biology Meeting, Washinton, DC, April 9-13, 2011.
120. Vin V, Leducq N, Bono F, Herbert JM. Binding characteristics of SSR180575, a potent and selective peripheral benzodiazepine ligand. Biochem Biophys Res Commun 2003; 310: 785-90.
121. James ML, Selleri S, Kassiou M. Development of ligands for the peripheral benzodiazepine receptor. Curr Med Chem 2006; 13: 1991-2001.
122. Maaser K, Sutter AP, Krahn A, Hopfner M, Grabowski P, Scherubl H. Cell cycle-related signaling pathways modulate. Biophy Res Commun 2004; 324: 878-86.
123. Maaser K, Neary JT, Jorgensen SL, Oracion AM, Bruce JH, Norenberg MD. Inhibition of growth factor-induced DNA synthesis in astrocytes by ligands of peripheral-type benzodiazepine receptors. Brain Res 1995; 675: 27-30.
124. Sutter AP, Maaser K, Hopfner M, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells. Int J Cancer 2002; 102: 318-27.
125. Maaser K, Hopfner M, Jansen A, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer 2001; 85: 1771-80.
126. Ratcliffe SL, Matthews EK. Modification of the photodynamic action of delta-aminolaevulinic acid (ALA) on rat pancreatoma cells by mitochondrial benzodiazepine receptor ligands. Br. J. Cancer 1995; 71: 300-5.
127. Okaro AC, Fennell DA, Corbo M, Davidson BR, Cotter FE. PK11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-XL and Mcl-1 expressing human cholangiocarcinoma cells. Gut 2002; 51: 556-61.
128. Veenman L, Papadopoulos V, Gavish M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharm Des 2007; 13(23): 2385-405.
129. Chelli B, Salvetti A, DaPozzo E, et al. PK-11195 differentially affects cell survival in human wild-type and 18-kDa translocator protein-silenced ADF astrocytoma cells. J Cell Biochem 2008; 105: 712-23.
130. Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int 2002; 40: 475-86.
131. Gonzalez-Polo RA, Carvalho G, Braun T, et al. PK-11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene 2005; 24: 7503-13
132. Camins A, Diez-Fernandez C, Pujadas E, Camarasa J, Escubedo E. A new aspect of the antiproliferative action of peripheral-type benzodiazepine receptor ligands. Eur J Pharmacol 1995; 272: 289-92.
133. Kunert-Radek J, Stepien H, Pawlikowski M. Inhibition of rat pituitary tumor cell proliferation by benzodiazepines in vitro. Neuroendocrinology 1994; 59: 92-6.
134. Mityk W, Palka MW, Karna E, Jrzabek K, Boujrad N, Knapp P. Antimitotic activity of high affinity ligands for peripheral benzodiazepine receptor (PBR) in some normal and neoplastic cell lines. Advances in Medical Science 2006; 51: 156-9.
135. Banker DE, Cooper JJ, Fennell DA, Willman C, Appelbaum FR, Cotter FE. PK-11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents, by mitochondrial and non-mitochondrial mechanisms. Leuk Res 2002; 26: 91-106.
136. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399: 483-7.
137. Hirsch T, Decaudin D, Susin SA, et al. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. Exp Cell Res 1998; 241: 426-34.
138. Walter RB, Pirga JL, Cronk MR, Mayer S, Appelbum FR, Barker DE. PK-11195, peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood 2006; 106(10): 3584-93.
139. Mukhopadhyay S, Guillory B, Mukherjee S, Das SK. Antiproliferative effect of peripheral benzodiazepine receptor antagonist PK 11195 in rat mammary tumor cells. Mol Cell Biochem 2010; 340: 203-13.
140. Jaykumar AR, Panickr KS, Norenberg MD. Effects on free radical generation by ligands of the peripheral benzodiazepine receptor in cultured neural cells. Effects on free radical generation by ligands of the peripheral benzodiazepine receptor in cultured neural cells. J Neurochem 2002; 83: 1226-34.
141. Tomasello F, Messina A, Lartigue L, et al. Outer membrane VDAC1 controls permeability transition of the inner mitochondrial membrane in cellulo during stress-induced apoptosis. Cell Res 2009; 19: 1363-76.
142. Veerman L, Shandlov Y, Gavish M. VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis. J Bioenerg Biomembr 2008; 40(3): 199-205.
143. Decaudin D, Casedo M, Nemati F, et al. Peripheral Benzodiazepine receptor ligand reverses apoptosis resistance of cancer cell in vitro and in vivo. Cancer Res 2002; 62: 1388-93.